You are here
Philip Gorwood, MD, PhD
Clinique des Maladies Mentales et de l’Encéphale (CMME), Centre Hospitalier Sainte-Anne, and Paris Descartes University, INSERM U894, Paris, France
Philip Gorwood is Professor of Psychiatry and Head of Department at the Clinique des Maladies Mentales et de l’Encéphale (CMME) at the Centre Hospitalier Sainte-Anne in Paris, France. He also teaches at the Paris Descartes University, and is Head of Team 1 of the Centre of Psychiatry and Neuroscience at the Institut National de la Santé et de la Recherche Médicale (INSERM), which is also in Paris. This team is dedicated to studying genetic vulnerability to psychiatric and addictive disorders.
Professor Gorwood received his medical degree from the University of Paris in 1992, and then specialized in psychiatry; he completed a PhD in genetics in1996 at the same university. His areas of interest include phenotypical definition, treatment trials, pharmacogenetics, and the genetics of major psychiatric disorders (schizophrenia, eating disorders, addiction, suicide, and mood disorders).
Professor Gorwood has published more than 200 scientific articles and many book chapters. He has served on editorial boards of 25 journals, and has an h-index of 42. He is one of the Editors-in-Chief of European Psychiatry, and is also Editor-in-Chief of the Progress in Mind: focus on alcohol use disorders Resource Centre. Professor Gorwood is now Treasurer and a member of the Core Organizing and Scientific Committee, Executive Committee, and board of the European Psychiatric Association. He joined the scientific advisory board on addictive disorders of the European College of Neuropsychopharmacology in 2009. In 2000, Professor Gorwood received the French National Academy of Medicine Award for his research on alcohol dependence.
Lectures & interviews
- Genes count – they are involved in the risk of having a dependence in your life.
- Two hypotheses to explain how dopamine genes are involved in alcohol dependence.
- Testing the inhibition process with the stop-signal reaction-time reveals an endophenotype shared by affected patients and non-affected relatives.
- Pharmacogenetic aspects can be relevant for everyday practice, when specific polymorphisms are significantly associated with higher chances of treatment success.